Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Revotar Biopharmaceuticals AG

Latest From Revotar Biopharmaceuticals AG

Revotar reports positive Phase II results of bimosiamose in COPD

Revotar Biopharmaceuticals of Germany has reported positive top-line results from a Phase II trial of inhaled bimosiamose, a pan-selectin antagonist for COPD. The company hopes to start a more extensive Phase II study by the start of 2012 with a view to conducting a Phase III trial in two years time, it told Scrip.


Revotar wins grant for R&D pipeline

The German federal state of Brandenburg has granted Revotar Biopharmaceuticals €2.5 million for the development of its pipeline of selectin antagonists in respiratory indications.

Dermatology Respiratory

Management and board changes at Revotar

Revotar Biopharmaceuticals (Germany) has appointed Ludwig Felber chief financial officer and member of the executive board, and elected Professor Dr Wolfgang Hartwig as supervisory board member. Revotar's CEO, Dr Martin Pöhlchen, has also been appointed to the additional role of president. Mr Felber is the co-founder and former managing director of investment bank Viscardi. Professor Hartwig is managing director of Pharma R&D Consulting and the former global head of pharmaceutical R&D at Bayer HealthCare's pharmaceutical division.

Germany Companies

Recent Financings of Private Companies (11/2008)

Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Revotar Biopharmaceuticals AG
  • Senior Management
  • Martin Pöhlchen, PhD, Pres. & CEO
    Ludwig Felber, CFO
    Gerhard Wolff, MD, EVP, R&D
  • Contact Info
  • Revotar Biopharmaceuticals AG
    Phone: (49) 3302 202 5010
    Neuendorfstrasse 24a
    Hennigsdorf, 16761